Table 3.
Survival analysis of clinicopathologic variables for overall survival (OS) and progression-free survival (PFS) in the adult group.
| Variable | One-year | Five-year | One-year | Five-year | P-value | |
|---|---|---|---|---|---|---|
| OS | OS | PFS | PFS | Log-rank test | ||
| % (SE) | % (SE) | % (SE) | % (SE) | OS | PFS | |
| Sex | 0.29 | 0.17 | ||||
| Male | 89.4 (0.06) | 71.3 (0.10) | 69.2 (0.09) | 58.0 (0.09) | ||
| Female | 100 | 78.5 (0.07) | 85.5 (0.06) | 67.3 (0.08) | ||
| Symptom | —* | —* | ||||
| Symptomless | 97.3 (0.03) | 78.5 (0.08) | 83.9 (0.06) | 68.2 (0.08) | ||
| Haematuria | 90.0 (0.07) | 78.5 (0.10) | 72.0 (0.10) | 59.7 (0.11) | ||
| Abdominal mass | —* | — | — | — | ||
| Flank pain | 100 | 51.4 (0.19) | 72.7 (0.13) | 51.9 (0.16) | ||
| Laterality | 0.80 | 0.78 | ||||
| Left | 93.6 (0.04) | 71.8 (0.10) | 78.5 (0.07) | 67.9 (0.09) | ||
| Right | 97.3 (0.03) | 78.2 (0.07) | 78.9 (0.07) | 60.2 (0.09) | ||
| Operation | 0.78 | 0.16 | ||||
| RN | 95.6 (0.03) | 75.9 (0.07) | 74.3 (0.06) | 57.5 (0.08) | ||
| NSS | 95.8 (0.04) | 72.6 (0.13) | 87.5 (0.07) | 75.4 (0.10) | ||
| pT stage | <0.01 | <0.01 | ||||
| T1/T2 | 100 | 90.0 (0.05) | 92.4 (0.04) | 82.4 (0.06) | ||
| T3/T4 | 82.4 (0.09) | 34.0 (0.13) | 36.7 (0.12) | 0 | ||
| Nuclear grade | 0.64 | 0.50 | ||||
| 1/2 | 95.3 (0.03) | 75.6 (0.07) | 79.7 (0.06) | 67.1 (0.07) | ||
| 3/4 | 96.0 (0.04) | 74.6 (0.10) | 77.2 (0.08) | 53.6 (0.13) | ||
| AJCC stage | <0.01 | <0.01 | ||||
| I/II | 100 | 91.9 (0.05) | 93.7 (0.04) | 88.9 (0.05) | ||
| III/IV | 85.7 (0.08) | 38.5 (0.12) | 46.6 (0.11) | 0 | ||
| Local lymph node metastasis | <0.01 | <0.01 | ||||
| LN+ | 84.2 (0.08) | 40.3 (0.13) | 40.0 (0.11) | 0 | ||
| LN− | 100 | 89.1 (0.05) | 93.9 (0.03) | 87.3 (0.05) | ||
| Vena cava tumour thrombosis | <0.01 | <0.01 | ||||
| Positive | 88.9 (0.11) | 22.2 (0.14) | 11.1 (0.11) | 0 | ||
| Negative | 96.6 (0.02) | 85.1 (0.05) | 88.6 (0.04) | 72.8 (0.06) | ||
| Adjuvant therapy | <0.01 | <0.01 | ||||
| None | 95.7 (0.04) | 87.7 (0.09) | 95.7 (0.04) | 85.2 (0.08) | ||
| Immunotherapy | 100 | 90.5 (0.07) | 86.4 (0.06) | 82.7 (0.07) | ||
| Targeted therapy | 88.9 (0.07) | 43.8 (0.12) | 44.4 (0.11) | 11.1 (0.07) | ||
| Tumour boundary | 0.35 | 0.02 | ||||
| Clear | 97.6 (0.02) | 80.0 (0.08) | 88.0 (0.05) | 71.1 (0.08) | ||
| Unclear | 92.6 (0.05) | 68.6 (0.09) | 65.2 (0.09) | 50.5 (0.10) | ||
RN, Radical nephrectomy; NSS, Nephron-sparing surgery; AJCC, American Joint Committee On Cancer; LN+, Lymph node positivity; LN−, Lymph node negativity; SE, Standard error; *No data or insufficient data for statistical analysis.